Roche doubles down on tau for Alzheimer’s, licensing UCB dru...

Roche already has one Alzheimer’s candidate in its pipeline targeting tau, but has added a second via a deal with Belgian drugmaker UCB worth up to $2 billion.

UCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasi...

Belgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, so is celebrating new late-stage data showing superiority to th

Failed trial puts future of UCB’s epilepsy drug padsevonil i...

UCB’s James Musick on embracing digital therapeutics

Digital has rapidly taken over the pharma industry, but many still don’t fully understand how to harness it.

Janssen trials ultrasound-guided approach to treating Crohn'...

In the highly competitive market for inflammatory diseases such as Crohn's, pharma companies are looking for ways to maximise benefits of already approved drugs, as well as

UCB/Amgen's Evenity approved in Europe after appeal

UCB and Amgen’s osteoporosis drug Evenity has finally been approved in Europe, following a successful appeal against a regulatory rejection, to become the first new drug for the condition s